Free Trial
→ Trump’s issues shocking Executive Order on U.S. Dollar (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:PRQR

ProQR Therapeutics Q3 2026 Earnings Date & Estimates

ProQR Therapeutics logo
$1.63 +0.06 (+3.82%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.03 (-1.84%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProQR Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from ProQR Therapeutics in Q3 2026

ProQR Therapeutics is expected to post earnings of -$0.11 per share on revenue of $4.30 million. In the same quarter a year earlier ProQR Therapeutics reported -$0.12 per share on revenue of $3.38 million. ProQR Therapeutics last reported on August 13, 2026, posting -$0.0914 per share and beating the -$0.1303 consensus estimate. ProQR Therapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.11
Expected Revenue
$4.30 million
Prior-Year EPS
-$0.12
Prior-Year Revenue
$3.38 million
Expected Revenue Growth
+27.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.0914 (Beat by +$0.0389)
Last Quarter Revenue
$10.00 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

ProQR Therapeutics Q3 2026 Earnings FAQ

ProQR Therapeutics (NASDAQ:PRQR) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

ProQR Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect ProQR Therapeutics to post earnings of -$0.11 per share for Q3 2026.

The consensus revenue estimate for ProQR Therapeutics is $4.30 million for Q3 2026.

ProQR Therapeutics Earnings Headlines

HC Wainwright Has Negative Estimate for PRQR FY2028 Earnings
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085444
Beam Therapeutics (NASDAQ:BEAM) and ProQR Therapeutics (NASDAQ:PRQR) Critical Contrast
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31084247
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Chardan Capital Reaffirms "Buy" Rating for ProQR Therapeutics (NASDAQ:PRQR)
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081530
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Target Cut by HC Wainwright
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081517
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)
October 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SGMT/pressreleases/4925506/analysts-offer-insights-on-healthcare-companies-proqr-prqr-and-sagimet-biosciences-inc-class-a-sgmt/
See More ProQR Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ProQR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ProQR Therapeutics and other key companies, straight to your email.

About ProQR Therapeutics

ProQR Therapeutics (NASDAQ:PRQR) is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR’s technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders. Its programs have included treatments intended to restore or improve the production of functional proteins affected by genetic mutations, although these therapies remain investigational and are not broadly approved medicines.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR has conducted research and development activities across Europe and the United States. The company has pursued collaborations with larger pharmaceutical organizations, including a strategic research collaboration with Eli Lilly focused on applying ProQR’s RNA-editing technology to potential new medicines.

View ProQR Therapeutics Profile
Earnings Tools